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Abstract
Background: Stress hyperglycaemia (SHG) is a common complication in sepsis associated with poor outcome.
Chemerin is an adipocytokine associated with inflammation and impaired glucose homeostasis in metabolic
diseases such as type 2 diabetes (T2D). We aimed to investigate how alterations of circulating chemerin levels and
corresponding visceral adipose tissue (VAT) expression are linked to glucose metabolism and prognosis in sepsis.
Methods: Clinical data and tissue samples were taken from a cross-sectional study including control, T2D and
sepsis patients, all undergoing laparotomy. A second independent patient cohort of patients with sepsis was
included to evaluate associations with prognosis. This was complemented by a murine model of peritoneal
infection and a high-fat diet. We analysed circulating chemerin by enzyme-linked immunosorbent assay and VAT
messenger RNA (mRNA) expression by real-time polymerase chain reaction.
Results: Circulating chemerin was increased in sepsis 1.69-fold compared with controls (p = 0.012) and 1.47-fold
compared with T2D (p = 0.03). Otherwise, chemerin VAT mRNA expression was decreased in patients with sepsis
(p = 0.006) and in septic diabetic animals (p = 0.009). Circulating chemerin correlated significantly with intra-operative
glucose (r = 0.662; p = 0.01) and in trend with fasting glucose (r = 0.528; p = 0.052). After adjusting for body mass index
or haemoglobin A1c, chemerin correlated in trend with insulin resistance evaluated using the logarithmised
homeostasis model assessment of insulin resistance (r = 0.539, p = 0.071; r = 0.553, p = 0.062). Chemerin was
positively associated with Acute Physiology and Chronic Health Evaluation II score in patients with sepsis
(p = 0.036) and with clinical severity in septic mice (p = 0.031). In an independent study population, we
confirmed association of chemerin with glucose levels in multivariate linear regression analysis (β = 0.556,
p = 0.013). In patients with sepsis with SHG, non-survivors had significantly lower chemerin levels than survivors
(0.38-fold, p = 0.006), while in patients without SHG, non-survivors had higher chemerin levels, not reaching significance
(1.64-fold, p = 0.089). No difference was apparent in patients with pre-existing T2D (p = 0.44).
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Conclusions: We show, for the first time to our knowledge, that chemerin is increased in sepsis and that it associates
with impaired glucose metabolism and survival in these patients. It could be further evaluated as a biomarker to stratify
mortality risk of patients with SHG.
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Background
Sepsis is defined as a state of high-grade systemic inflam-
mation caused by infection. This is accompanied by
severe dysregulation of glucose homeostasis, including
insulin resistance and stress hyperglycaemia (SHG) [1]
as common complications associated with poor outcome
[2] and post–intensive care unit (post-ICU) diabetes [3].
Besides glucocorticoid and catecholamine effects, in-
sulin resistance is thought to be caused mainly by
pro-inflammatory cytokines in sepsis [1]. These con-
nections have been studied mainly in obesity-related
diseases but are poorly characterised in sepsis. Deeper
insights into these mechanisms may serve to reveal
new therapeutic targets to control homeostasis as well as
diagnostic and prognostic biomarkers of host response.
Adipokines have been receiving more attention in re-
cent research in this area, as they are found to be related
to inflammation, disturbed glucose metabolism and even
disease severity in sepsis [4]. Chemerin (retinoic acid
receptor responder 2 (RARRES2); NCBI Reference
Sequence: [NM_002889]) is expressed mainly by adipose
tissue [5]. Additional sites of expression include the liver,
pancreas and adrenal gland [6, 7]. The inactive pro-
chemerin is processed by serine and cysteine proteases,
resulting in various chemerin isoforms with different
activities and spatiotemporal distributions [8]. Known ef-
fects of chemerin include chemoattraction and activation
of antigen-presenting cells, resulting in infiltration of
leucocytes to different sites of inflammation and tissue
damage [9] while retaining neutrophil granulocytes in
the circulation [10, 11]. Systemic chemerin administra-
tion results in whole-body insulin resistance [12] and
differentially regulates insulin sensitivity in different cell
types, such as adipocytes [13] and muscle cells [14, 15].
Clear evidence exists as well for anti-inflammatory
[10, 11, 16] and anti-microbial [17] properties of
chemerin. Chemerin effects are mediated mainly by
binding to its receptor chemokine-like receptor 1
(CMKLR1, also known as ChemR23) on CMKLR1+
cells such as leucocyte subpopulations, adipocytes and
hepatocytes [6], as well as by endothelial activation
[18]. C-C chemokine receptor-like 2 (CCRL2) and G
protein–coupled receptor 1 (GPR1) are additional chemerin
receptors responsible for modulating local chemerin
activity [9]. Chemerin is thought to play a role in
different metabolic, inflammatory and autoimmune
processes such as metabolic syndrome [19], non-alcoholic
fatty liver disease [20, 21], rheumatoid arthritis [22],
chronic inflammatory bowel disease [23] and chronic pan-
creatitis [24].
On the basis of mechanisms of chemerin action, one
can hypothesise that it is involved in differential leuco-
cyte recruitment and regulation of inflammation, thereby
modulating sepsis disease severity. At the same time,
chemerin might participate in induction of insulin resist-
ance and thus contribute to development of SHG.
Thereby, chemerin is a possible link between systemic
inflammation and insulin resistance in sepsis host re-
sponse. However, chemerin has not been investigated in
sepsis yet. Hence, we aimed to study chemerin in the
context of sepsis host response in a clinical cross-
sectional study with type 2 diabetes (T2D) as a positive
control. We focused on changes in serum levels and
their association with disturbed glucose metabolism, dis-
ease severity and prognosis. Furthermore, we wanted to
evaluate the suitability of the murine peritoneal contam-
ination and infection (PCI) model of peritoneal sepsis in
combination with a T2D model for studying chemerin in
the context of sepsis.
Methods
Study design
The main part of this study was a cross-sectional
clinical analysis of chemerin and its associations with
parameters of inflammation and disturbed glucose
metabolism in patients with sepsis, T2D or none of
the aforementioned diseases. We included patients
with T2D as positive controls, in whom chemerin has
already been described to be increased [25], and pa-
tients without metabolic co-morbidities or sepsis as
negative control subjects. We took blood and visceral
adipose tissue (VAT) samples from patients undergo-
ing therapeutic laparotomy and collected data from
standard laboratory measurements. We included
blood samples and data from an independent cross-
sectional study to validate associations with prognosis
(validation cohort).
Clinical studies were complemented by a murine
model of polymicrobial peritoneal sepsis. To accord with
the study design of our clinical study, we included a
murine diabetes model by feeding mice a high-fat diet
(HFD).
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Clinical study subjects and ethics
Clinical tissue samples from the first study cohort were
obtained from study subjects who were enrolled in the
INSIGHT study, which is registered in the German Clin-
ical Trials Register (DRKS00005450). As a second inde-
pendent study population, we selected all consecutive
patients from the HMOX study who had an abdominal
focus of sepsis. The study approval was given by the fac-
ulty ethics review board of Jena University Hospital
(INSIGHT: 3247-09/11 and validation cohort: 3624-11/
12, 2712-12/09, 2160-11/07). All subjects or their legal
representatives gave written informed consent and
principal investigators of the original trials approved
publication of this article. Inclusion and exclusion cri-
teria for the two studies are provided in Additional
file 1: Table S1. For intergroup comparison analyses,
we included subgroups with ten patients each.
The diagnosis of sepsis was made following criteria of
the S2k guidelines of the German Sepsis Society [26]. Pa-
tients with T2D fulfilled the 2010 criteria of the American
Diabetes Association for a diagnosis of T2D [27] or had
known T2D treated with oral anti-diabetic therapy. In
addition to the exclusion criteria provided in Additional
file 1: Table S1, control patients had no sepsis, T2D or
metabolic syndrome as defined by National Cholesterol
Education Program Expert Panel on Detection Evaluation,
and Treatment of High Blood Cholesterol in Adults
(Adult Treatment Panel III) criteria [28]. Alcohol abuse as
an exclusion criterion was defined as a daily alcohol intake
of more than 20 g for females and more than 40 g for
males [29]. Each patient’s medical history was evaluated,
and body mass index (BMI) was calculated for each pa-
tient. We calculated Acute Physiology and Chronic Health
Evaluation II (APACHE II) score [30] and Simplified
Acute Physiology Score II [31] as described elsewhere in
the literature. In the second study cohort, we assigned pa-
tients to the newly diagnosed SHG subgroup on the basis
of routine glucose measurements during the ICU stay ac-
cording to predefined criteria [32].
Human blood and tissue sampling
Control and T2D subjects of the first study cohort were
fasted overnight, and peripheral blood was taken the
morning before surgery. Blood from sepsis subjects was
taken on the morning after surgery to obtain blood after
an overnight fast, as a fasting period before surgery was
not feasible. In the second, independent study cohort,
blood was taken within 24 h of sepsis diagnosis. Serum
was obtained by centrifugation and stored at −80 °C.
VAT samples were taken right after mid-line incision
and adhesiolysis from the greater omentum and immedi-
ately snap-frozen [33] in liquid nitrogen and stored at
−80 °C. Blood samples of the second study cohort were
taken on the morning of study enrolment.
To assess insulin resistance, we calculated the
homeostasis model assessment of insulin resistance
(HOMA-IR) [34] on the basis of fasting glucose and
insulin levels. As an assessment of long-term gly-
caemia, we measured glycated haemoglobin A1c
(HbA1c) by means of standard laboratory methods.
All laboratory analyses were performed in certified
clinical chemistry laboratories of Jena University
Hospital.
Confirmational exploration in an animal model
We performed all investigations and experiments in ac-
cordance with the German legislation on protection of
animals and obtained permission to conduct the study
from the regional animal welfare committee (registration
number 02-038/12). Six-week-old male C57BL/6 J mice
were kept under standardised laboratory conditions and
were fed a standard rodent chow [control diet (CD)] or
an HFD (EF R/M D12492 modified diet; ssniff, Soest,
Germany) containing 34 % fat for 12 weeks. HFD served
as a model of obesity-induced T2D [35] to reflect our
clinical study design. We weighed the mice every 2 weeks
to check for adequate feeding and weight development.
Intra-peritoneal glucose tolerance tests were performed
to verify diabetes-like phenotype. Therefore, the mice
were given intra-peritoneal injections of 2 g/kg body
weight glucose, and full blood glucose levels were mea-
sured at 0, 30, 60, 90 and 120 minutes after injection.
Areas under the curve were calculated and compared
between groups.
After 12 weeks of feeding, we randomised animals into
four groups: CD baseline (CD0h), HFD baseline (HFD0h),
CD sepsis (CD24h) and HFD sepsis (HFD24h). Sepsis was
induced using the PCI model as described previously
[36]. Briefly, a standardised and diluted suspension of
human faecal slurry (1.25 μl/g body weight) was admin-
istered intra-peritoneally. Disease severity was assessed
by using the Clinical Severity Score (CSS) as described
elsewhere [36]. Twenty-four hours after sepsis induction,
mice were killed while in deep isoflurane anaesthesia by
taking citrate anti-coagulated blood by heart puncture.
Plasma was made by centrifugation and stored at −80 °C.
Epididymal fat pads were collected as VAT samples and
immediately snap-frozen in liquid nitrogen and stored
at −80 °C.
Quantification of circulating chemerin
Circulating chemerin concentrations were measured
from human serum and murine citrate anti-coagulated
plasma. The enzyme-linked immunosorbent assays
(ELISAs) used were the Human Chemerin ELISA kit
(BioVendor, Kassel, Germany) and Mouse Chemerin
Quantikine ELISA Kit (R&D Systems, Minneapolis,
MN, USA). We performed ELISAs according to the
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manufacturer’s instructions, measured all samples in
duplicates and calculated the means.
VAT mRNA expression
We extracted VAT messenger RNA (mRNA) using the
RNeasy Lipid Tissue Mini Kit (QIAGEN, Hilden,
Germany) according to the manufacturer’s instructions.
RNA concentration was measured by spectrophotometry
with the NanoDrop 1000 instrument (NanoDrop Products/
Thermo Scientific, Wilmington, DE, USA). The integrity of
the RNA was checked by automated electrophoresis with
the Experion Automated Electrophoresis System (Bio-Rad
Laboratories, Hercules, CA, USA). Reverse transcription of
RNA into complementary DNA (cDNA) was achieved
by using the Fermentas RevertAid First Strand cDNA
Synthesis Kit (Thermo Scientific, Grand Island, NY,
USA) according to the manufacturer’s instructions.
Real-time quantitative polymerase chain reactions
(RT-qPCR) were performed using the Rotor-Gene Q
cycler (QIAGEN).
For RT-qPCR analysis, we used the primers listed in
Additional file 1: Table S2. Relative expression for each
primer was interpolated from standard curves. After
housekeeping gene analysis using geNorm [37] and
NormFinder [38] software, the means of relative expres-
sion of β actin, glyceraldehyde 3-phosphate dehydrogen-
ase (GAPDH), hypoxanthine phosphoribosyltransferase
1 (HPRT) and porphobilinogen deaminase (PBGD) were
calculated and used as normalisation factors in clinical
studies and Gapdh and Hprt in mouse studies. Normal-
ised gene expression is given as relative expression of
the gene of interest divided by the normalisation factor
for each sample.
Statistical analysis
IBM SPSS Statistics version 22.0 software (IBM,
Armonk, NY, USA) was used to perform statistical
analyses. An alternative hypothesis was accepted as a
two-sided p < 0.05. All data are given as mean ±
standard error of the mean if not stated otherwise.
Normal distribution was tested with the Shapiro-
Wilk test, and decade logarithmic transformation
was used if required. To test for homogeneity of
variance, we used Levene’s test. Depending on data
distribution, we used the following statistical proce-
dures: one-way analysis of variance with post hoc
Bonferroni adjustment, Kruskal-Wallis test or Mann-
Whitney U test. To test for correlation, Pearson’s
simple correlation coefficient or Spearman’s rank
correlation coefficient was applied. Multivariate lin-
ear regression analysis was applied with circulating




The characteristics of patients in the first study
cohort are provided in Table 1. The groups were dif-
ferent in terms of age (p < 0.001), BMI (p = 0.003),
HbA1c (p < 0.001) and HOMA-IR (p = 0.022). Patients
with sepsis were comparable to subjects with T2D
with respect to age (p = 0.80), BMI (p = 0.52) and
HOMA-IR (p = 0.44) and comparable to control sub-
jects with respect to HbA1c (p = 0.13). Indications for
surgery were not different between control and T2D
subjects (Additional file 1: Table S4), with a higher
number of primary hepatic or biliary malignancies in
patients with T2D. Patients in the sepsis group under-
went emergency or high urgent surgery for different
indications. T2D and sepsis patients were matched ac-
cording to age and BMI to make these groups of our
main interest more comparable for subgroup com-
parison analyses. The patient characteristics of these
subgroups are provided in Additional file 1: Table S3.
In a second independent study cohort, we included
samples of 37 patients with peritoneal sepsis. We cate-
gorised these patients into three groups according to
their glycaemic status during their ICU stay: patients
without SHG, patients with previously diagnosed T2D
and patients with SHG but without a history of diabetes
mellitus. The characteristics of the second study cohort
are shown in Table 2. Groups were different in terms of
age and BMI, with significantly younger and leaner pa-
tients in the SHG group.
In mice, HFD induced substantial and significant
weight gain compared with the CD (Additional file 2:
Fig. S1A). In accordance with a diabetes-like phenotype
of HFD-fed mice, impaired glucose tolerance and higher
baseline glucose levels were observed (Additional file 2:
Fig. S1).
Circulating chemerin and mRNA VAT expression
Circulating chemerin levels in human sepsis were sig-
nificantly increased by 1.69-fold compared with con-
trols (p = 0.012) and by 1.47-fold compared with T2D
(p = 0.03) (Fig. 1a). No significant difference was ob-
served between controls and T2D (p = 0.87) (Fig. 1a).
In patients with sepsis, we observed a strong positive
correlation of chemerin with blood leucocyte count
(p = 0.02) and thrombocyte count (p = 0.03), but not
with C-reactive protein (CRP), interleukin-6 or glom-
erular filtration rate (Additional file 1: Table S5). No
such significant correlations were found in the valid-
ation cohort (Additional file 1: Table S6). Other asso-
ciations of chemerin with clinical characteristics are
shown in Additional file 1: Table S5 and Table S6.
VAT mRNA expression of chemerin was markedly
lower in patients with sepsis compared with T2D
Horn et al. Critical Care  (2016) 20:39 Page 4 of 12
(p = 0.012) and controls (p = 0.009) (Fig. 1b). No
difference between controls and T2D was apparent
(p = 0.80). Expression of CMKLR1 was increased in
patients with T2D compared with controls (p = 0.029) but
was not altered in sepsis (Fig. 1b), while CCRL2
mRNA was increased in patients with sepsis com-
pared with controls (p = 0.031; Fig. 1b) and no signifi-
cant differences among groups were observed for
GPR1 (Fig. 1b).
In concordance with the clinical results, circulating
chemerin levels were significantly different across all
mouse groups (p = 0.003), with the highest levels in sep-
tic mice (Fig. 1c). Murine chemerin mRNA levels in
VAT were reduced in HFD24h and CD24h undergoing
sepsis compared with HFD0h (p = 0.009 and p = 0.012,
respectively) but not CD0h (p = 0.53 and p = 0.75,
respectively) (Fig. 1d). Cmklr1 mRNA was significantly
decreased in both CD and HFD mice following sepsis
(p = 0.001 and p < 0.001, respectively) (Fig. 1d), while
Ccrl2 mRNA was increased (p = 0.024 and p = 0.012,
respectively) (Fig. 1d). Murine Gpr1 mRNA was not
significantly different among groups (Fig. 1d).
Table 1 Characteristics of the first study cohort
Control T2D Sepsis p Value
Number of subjects 17 20 14 –
Male sex, % 30 80 57 0.008a
Age, yr 56 ± 3b 68 ± 1c 69 ± 3c <0.001
BMI, kg/m2 24.8 ± 1.0b 28.9 ± 0.9c 29.5 ± 1.2c 0.003
HbA1c, % 5.5 ± 0.1b 7.8 ± 0.4c 5.9 ± 0.3b <0.001
HOMA-IR, AU 1.5 ± 0.3b 5.6 ± 1.4c 4.3 ± 1.3c 0.022
GFR, ml/min 95.3 ± 3.0b 70.8 ± 3.7c 44.9 ± 10.5 <0.001
CRP, mg/L 3.5 ± 0.5b 15.9 ± 9.5c 220.5 ± 26.8d <0.001
Malignancy, % 65 80 64 0.736a
Duration of ICU stay, days 7.8 ± 2.1 –
ICU non-survivors, n 5/14 –
Abbreviations: BMI body mass index, CRP C-reactive protein, GFR glomerular filtration rate, HbA1c haemoglobin A1c, HOMA-IR homeostasis model assessment of in-
sulin resistance, ICU intensive care unit, T2D type 2 diabetes mellitus
Data are given as mean ± SEM, absolute numbers or median and interquartile range. For comparison of groups, the Kruskal-Wallis test and post hoc Bonferroni ad-
justment were used. Superscript letters indicate significant differences between subgroups (p<0.05)
aχ2 test
Table 2 Characteristics of the validation cohort
Glycaemic status on ICU
All No SHG T2D New SHG p Value
Number of subjects 37 11 11 15
Male sex, % 65 64 64 67 0.982a
Age, yr 63 ± 2 68 ± 3b 70 ± 2b 54 ± 4c 0.002
BMI, kg/m2 27.8 ± 1.0 28.0 ± 2.2b 31.2 ± 2.0b 25.2 ± 1.1b 0.064
Glucose mmol/L 6.8 ± 0.3 6.6 ± 0.3 6.5 ± 0.6 7.2 ± 0.4 0.264
GFR ml/min 62.4 ± 6.9 62.3 ± 11.0b 39.8 ± 8.0b 80.4 ± 12.8b 0.033
CRP mg/L 142.0 ± 18.8 149.4 ± 39.3b 170.7 ± 37.4b 115.6 ± 95.8b 0.477
Diabetes mellitus 12/37 0/11 11/11 0/15 <0.001a
Renal replacement therapy 3/37 1/11 1/11 1/15 0.965a
APACHE II score 21 (18–28) 20b (18–25) 27b (20–33) 21b (15–26) 0.185
SAPS II 49 (37.0–64.5) 48b (42.0–65.0) 63b (48.0–71.0) 45b (31.0–54.0) 0.112
28-day mortality, n (%) 10/37 (27) 4/11 (36) 2/11 (18) 4/15 (27) 0.628a
Abbreviations: APACHE II Acute Physiology and Chronic Health Evaluation, BMI body mass index, CRP C-reactive protein, GFR glomerular filtration rate, ICU intensive
care unit, SAPS II Simplified Acute Physiology Score, SHG stress hyperglycaemia, T2D type 2 diabetes
Data are given as mean ± standard error of the mean, absolute numbers or median and interquartile range. For comparison of groups, the Kruskal-Wallis test and
post hoc Bonferroni adjustment were used. Superscript letters indicate significant differences between subgroups (p<0.05)
aχ2 test
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Association with parameters of glucose metabolism
In patients with sepsis, circulating chemerin corre-
lated in trend with fasting glucose levels (r = 0.528,
p = 0.052) (Fig. 2a) and significantly with logarith-
mised intra-operative glucose levels (r = 0.662, p = 0.01)
(Fig. 2b). In control patients, we found comparable signifi-
cant positive correlations of chemerin with intra-operative
glucose (r = 0.549, p = 0.023) (Additional file 3: Fig. S2)
and fasting glucose levels (r = 0.516, p = 0.034) (Additional
file 3: Fig. S2), while no significant correlations were found
in patients with T2D (Additional file 4: Fig. S3). After
adjusting circulating chemerin levels by dividing by BMI
or HbA1c, chemerin correlated with logarithmised
HOMA-IR, but without reaching significance (r = 0.539,
p = 0.071, and r = 0.553, p = 0.062, respectively) (Fig. 2c
and d). Because two values of HOMA-IR equalled 0,
those values dropped out for logarithmised analysis. In
control subjects and patients with T2D, no correlation
of chemerin and HOMA-IR was apparent (data not
shown).
In the second independent study cohort, we did not
observe a significant association of chemerin with glu-
cose levels (Additional file 1: Table S6). However, after
exclusion of patients with SHG, chemerin was positively
and significantly correlated to glucose levels (r = 0.438,
p = 0.041) (Fig. 2e), while no correlation was observable
in SHG (r = −0.063, p = 0.82) (Fig. 2f ). In a multivariate
linear regression model, circulating chemerin was sig-
nificantly and independently associated with glucose
levels in patients without SHG (β = 0.556, p = 0.013)
(Model Sepsis C; see Table 3).
Association with and disease severity
In the primary study group, chemerin was not associated
with 28-day survival after sepsis onset (Fig. 3a), but we
found increased chemerin levels in patients with an
APACHE II score higher than 24 points at study enrol-
ment (p = 0.036) (Fig. 3b) [30]. In concordance with
these results, an increased CSS [36], as an assessment of
sepsis disease severity in rodents, was significantly ac-
companied by higher levels of circulating chemerin in
septic mice (p = 0.031) (Fig. 3c).
In the next step, we aimed to evaluate prognostic
associations of chemerin in our second independent
study cohort. In patients with SHG, survivors dis-
played significantly higher chemerin levels than non-
survivors (p = 0.006) (Fig. 3d). In contrast, survivors dis-
played lower chemerin levels than non-survivors in pa-
tients without SHG, not reaching significance (p = 0.089)
(Fig. 3d). No such association was visible in patients with
sepsis with pre-existing T2D (p = 0.436) (Fig. 3d).
Excluding patients with T2D for further analyses, we
retrospectively defined two risk groups: (1) patients with-
out SHG and chemerin levels higher than 200 ng/ml and
(2) patients with SHG and chemerin levels lower than
100 ng/ml. Assigning patients retrospectively into one of
those groups resulted in a sensitivity of 75 % and a specifi-
city of 89.5 % for detecting death at day 28 after sepsis on-
set. The positive predictive value for this population was
85.7 %, and the negative predictive value was 94.4 %.
Patients assigned to one of the two risk groups had an
8.1-fold incidence of death during the first 28 days of sep-
sis (95 % confidence interval 2.1–31.5, p < 0.05).
Fig. 1 Circulating levels and visceral adipose tissue mRNA expression of chemerin. One-way analysis of variance with Bonferroni adjustment,
Kruskal-Wallis test or Mann-Whitney U test with Bonferroni-Holm adjustment were applied (*p<0.05). a Circulating chemerin levels in matched
clinical study subjects. b mRNA expression of chemerin and its receptors in VAT of matched clinical study subjects. c Circulating chemerin levels
in the mouse model of diabetes and sepsis (n = 5 or 6 per group). d mRNA expression of chemerin and its receptors in VAT of diabetic and septic
mice (n = 5 or 6 per group). VAT visceral adipose tissue, AU arbitrary units, CCRL2 C-C chemokine receptor-like 2, CMKLR1 chemokine-like receptor
1, GPR1 G protein–coupled receptor 1, T2D type 2 diabetes, mRNA messenger RNA, n.s. not significant, CD0h control diet baseline, HFD0h high-fat
diet baseline, CD24h control diet sepsis, HFD24h high-fat diet sepsis
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Discussion
In our cross-sectional study, we found increased circu-
lating chemerin levels and reduced VAT chemerin
mRNA in patients with peritoneal sepsis. In addition, we
found associations of chemerin with glucose metabolism,
disease severity and prognosis. The major findings of the
clinical study were supported in a murine model of sep-
sis and diabetes.
As a distinct advantage, we provide highly charac-
terised study subjects and adipose tissue gene expression
data. Due to the study design with the need for VAT
samples and thus an indication for open abdominal sur-
gery, our number of study subjects was limited. How-
ever, our study yielded significant differences supported
by our animal model, indicating sufficient power and
validity. Our study subjects in the primary study cohort
were representative of common surgical patients under-
going abdominal surgery, including a high incidence of
malignant disease. By enrolling patients with T2D as
intended positive controls, we were able to compare pa-
tients with sepsis with high-grade inflammation and
acute disturbance of glucose metabolism with those who
had low-grade inflammation and chronic disturbance of
glucose metabolism. This is represented by high CRP,
low HbA1c and high HOMA-IR in sepsis and lower
CRP, high HbA1c and high HOMA-IR in T2D. Age and
obesity are risk factors for both development of T2D
[27] and sepsis [39], which is why both study groups
were different from controls with regard to age and
BMI. We intended to include patients with T2D as posi-
tive controls, referring to previous reports of increased
chemerin levels in T2D [25]. However, we failed to re-
produce these results, most likely due to co-morbidities
in the control group, as chemerin levels in healthy con-
trol subjects are reported to be lower than we describe
[7]. Indications for surgery were comparable between
controls and patients with T2D, while indications were
substantially different in patients with sepsis, due to the
nature of the disease.
Our study is the first, to our knowledge, to demon-
strate increased circulating chemerin levels in sepsis host
response. This increase exceeds elevated values, as found
in other diseases with either low- or high-grade inflam-
mation as a substantial component such as metabolic
syndrome [5] and T2D [40], inflammatory bowel disease
[23], chronic pancreatitis [24] and rheumatoid arthritis
[41]. Chemerin values in the control group exceeded
normal values described in young healthy women, ran-
ging from 160 ng/ml in the fed state to 55 ng/ml in the
fasted state [7]. Therefore, our concept of selecting T2D
as a positive control condition failed.
Epitope recognition of available ELISAs is not suitable
for differentiating distinct chemerin isoforms and is
therefore unable to distinguish unprocessed, inactive
prochemerin- and proteolysis-activated chemerin. Hence,
it can be hypothesised whether increased chemerin levels
in sepsis correspond to increased activity. An activation of
chemerin in sepsis host response is likely, as it is activated
by serine and cysteine proteases of neutrophil granules
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Fig. 2 Association of chemerin with markers of disturbed glucose
homeostasis. Pearson’s simple coefficient or Spearman’s rank
correlation coefficient was used for correlation analyses. a Correlation
of circulating chemerin levels with fasting glucose levels (r = 0.528,
p = 0.052, n = 14). b Correlation of circulating chemerin levels with
logarithmised intraoperative (OP) glucose in subjects with sepsis
(r = 0.662, p = 0.01, n = 14). c Correlation of BMI-adjusted circulating
chemerin levels with HOMA-IR (r = 0.539, p = 0.071, n = 12). d
Correlation of HbA1c-adjusted circulating chemerin levels with
HOMA-IR after adjusting for BMI (r = 0.553, p = 0.062, n = 12).
e Correlation of circulating chemerin levels with glucose levels
in the second study cohort after exclusion of patients with SHG
(r = 0.438, p = 0.041, n = 22). f Correlation of circulating chemerin
levels with glucose levels in patients with SHG in the second study
cohort (r = −0.063; p = 0.823, n = 15). AU arbitrary units, BMI body
mass index, HbA1c haemoglobin A1c, HOMA-IR homeostasis model
assessment of insulin resistance, SHG stress hyperglycaemia
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activated in sepsis [42, 43]. As our independent study co-
hort was not designed to reproduce results of increased
chemerin, an appropriate non-septic control group is lack-
ing. However, data regarding increased chemerin in sepsis
are supported by our mouse model of sepsis and diabetes,
as we observed a stepwise increase of chemerin levels with
metabolic disease induced by HFD, high-grade inflamma-
tion induced by PCI and the combination of both. Because
in the literature both glucose homeostasis and inflamma-
tion are associated with chemerin levels [9–15], we inter-
pret our results as a kind of a dose-dependent effect on
circulating chemerin.
We analysed chemerin mRNA expression in VAT, as it
is described as a main site of chemerin production [5].
Surprisingly, we found decreased chemerin mRNA ex-
pression in sepsis, despite its increased circulating levels.
Chemerin mRNA has been shown to be positively regu-
lated by peroxisome proliferator-activated receptor γ
[44], which in turn is downregulated in response to in-
flammation in adipocytes [45]. Likewise, chemerin
mRNA is upregulated by insulin [44], but insulin signal-
ling may be disrupted in adipose tissue due to insulin re-
sistance. However, chemerin secretion is not necessarily
related to chemerin mRNA levels [46], whereby de-
creased chemerin mRNA expression may not necessarily
result in decreased chemerin secretion by VAT. Our
PCR results may be biased because we measured mRNA
levels only in whole-tissue homogenates, but adipose tis-
sue is comprised of many different cell types. Endothelial
activation is shown to increase chemerin mRNA expres-
sion in endothelial cells [18], an effect that may have
been obscured by mRNA downregulation in other cell
types. Other possible sources for increased chemerin
levels in the circulation are secretion from liver, pancreas
or adrenal glands [7, 20, 40], but those organs were be-
yond the scope of our explorative study. Another ex-
planation for increased levels of circulating chemerin
levels would be changes in receptor expression. Absent
CMKLR1 or CCRL2 protein in knockout mice is associ-
ated with increased chemerin levels [47, 48]. We did ob-
serve a substantial downregulation of CMKLR1 in our
mouse model, but not in human VAT. Thereby de-
creased CMKLR1 expression could at least in part con-
tribute to increased chemerin levels. We observed
increased CCRL2 mRNA expression levels in human
and murine VAT, which is described to happen in re-
sponse to endothelial activation [48]. Thus, increased
CCRL2 expression is unlikely to contribute to increased
chemerin levels. Changes in GPR1 mRNA are unlikely
to contribute, as knockout of GPR1 in mice does not
change chemerin concentration [49] and we did not ob-
serve changed GPR1 expression.
The literature strongly suggests a role for inflamma-
tion and impaired renal function in elevation of che-
merin levels in sepsis [9, 50]. While we did not observe
consistent significant associations with inflammation or
renal function in patients with sepsis, the T2D and sepsis
groups in the primary study cohort were comparable in
means of age, sex, BMI and HOMA-IR. As the increase
in sepsis patients therefore cannot be completely
Table 3 Multivariate linear regression analysis with blood
glucose
Model Sepsis C
Dependent variable: blood glucose
β coefficient (p value)
Independent variables R = 0.800; R2 = 0.640; adjusted
R2 = 0.431, p = 0.043
Sex −0.023 (0.920)
Age 0.118 (0.549)
Log BMI −0.506 (0.096)
Circulating chemerin 0.556 (0.013)
Blood Urea −0.773 (0.004)
Log bilirubin 0.104 (0.618)
Log lactate −0.449 (0.048)
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Fig. 3 Circulating chemerin and markers of prognosis and disease
severity. The Mann-Whitney U test or the Kruskal-Wallis test was
applied (p<0.05). a Circulating chemerin was not significantly
different between survivors and non-survivors of sepsis in the first
study group. b Elevated circulating chemerin in sepsis subjects with
an APACHE II score higher than 24 (p = 0.036). c Increased circulating
chemerin levels with higher Clinical Severity Score in septic mice
(n = 2 for scores 2 and 3, n = 7 for score 4). d Chemerin levels,
depending on survival status of patients with sepsis without stress
hyperglycaemia (SHG), with pre-existing type 2 diabetes mellitus or
with SHG in the second study group. APACHE II Acute Physiology
and Chronic Health Evaluation
Horn et al. Critical Care  (2016) 20:39 Page 8 of 12
attributed to altered glucose homeostasis, we assume
that inflammation as well as impaired renal function
may be responsible as additional influencing factors.
In both study cohorts, chemerin was clearly associ-
ated with parameters of disturbed glucose homeostasis
and insulin resistance, excluding patients with SHG. It
is well known that chemerin is associated with BMI [5],
hyperinsulinemia [51], insulin resistance [52, 53] and
dyslipidaemia [54] in diseases associated with develop-
ment of the metabolic syndrome, such as T2D.
Chemerin induces insulin resistance in muscle cells
[14, 15] and promotes insulin sensitivity in adipocytes
[13] in vitro. In vivo administration [12] or adenoviral
overexpression of chemerin [15] promotes glucose in-
tolerance and insulin resistance. Thereby increased
circulating chemerin is likely to contribute to dis-
turbed glucose homeostasis, insulin resistance and de-
velopment of SHG in sepsis. Interactions of chemerin
with other adipokines might be involved in regulation
of glucose homeostasis [4], but they were beyond the
scope of our study.
Furthermore, we evaluated associations of chemerin
with disease severity and 28-day mortality. Chemerin
was associated with the APACHE II score in the clinical
study and with disease severity in the mouse model, im-
plying chemerin as being of prognostic value. In our
primary study group, we could not observe differences
in chemerin levels between survivors and non-
survivors. As the number of studied patients was rather
small, a separate analysis of patients with SHG was not
feasible. We included a second independent study co-
hort comprised of patients with abdominal sepsis to
further investigate the association of chemerin with
prognosis. Interestingly, we found inverse associations
of chemerin with 28-day mortality, depending on gly-
caemic status. As the number of patients was very small
for each group, our data have to be interpreted care-
fully. Also, it must be noted that patients with SHG
were significantly younger and leaner than patients
without SHG, which may reflect different underlying
diseases. Additionally, chemerin failed to associate with
glucose levels in patients with SHG, indicating different
functional mechanisms of chemerin in this group.
Though we did not investigate chemerin isoforms, dif-
ferential chemerin processing may be a possible ex-
planatory approach for this difference, as different
isoforms have opposite functions in regulation of in-
flammation [44].
Novel data of chemerin function support the concept
that chemerin is not a pro- or anti-inflammatory agent
per se, but initiates infiltration of immunomodulatory
CMKLR1+ cells [44], which then can initiate pro- or
anti-inflammatory reactions, depending on other fac-
tors in the local milieu. An adaptive function of
chemerin is supported by previous findings of direct
anti-microbial effects [17, 55], and protective effects
against lung inflammation and zymosan induced peri-
tonitis [10, 11, 16]. In patients without SHG, chemerin
was associated mainly with glucose levels. Adverse
prognostic associations in this group thereby might be
mediated by adverse effects of higher glucose levels [2].
Prospective studies are needed to confirm prognostic
associations of chemerin, taking into account glycaemic
status of patients and chemerin isoforms. Comparative
studies in critically ill patients without sepsis are
needed to provide evidence for whether these associa-
tions are specific for sepsis or generalisable for critical
illness.
The PCI model of sepsis reflects the main charac-
teristics of human sepsis [36]. The main findings of
our clinical studies regarding circulating chemerin, its
VAT gene expression and associations with disease se-
verity were reproducible in the mouse model, but
substantial differences between human and murine
chemerin have been reported. Circulating chemerin
levels show day–night variations in mice [46] but not
in humans [7]. Chemerin mRNA expression patterns
are reported to be different, with high adipose tissue
expression in mice [56] and low adipose tissue ex-
pression in humans [7]; however, open access tran-
scriptomic data indicate moderate to high chemerin
expression in adipose tissue in humans as well [57].
Regarding the dependency of chemerin on the gly-
caemic status of patients with sepsis, no reliable ani-
mal models for SHG are available so far. Besides all
its limitations, the PCI model of peritoneal sepsis and
the HFD model of obesity-induced T2D seem to be
suitable for studying chemerin function in sepsis host
response in an appropriate manner.
Conclusions
To the best of our knowledge, this report is the first to
describe altered circulating chemerin levels in sepsis.
Chemerin was found to be linked to disturbed glucose
metabolism and may play a differential role in the patho-
genesis of SHG. Additionally, we found chemerin to be
associated with disease severity. It may even be suitable
as a prognostic factor, depending on the glycaemic status
of patients with sepsis. Our results imply differential
mechanistic functions in patients with SHG. Our main
clinical results were reflected in the PCI model of sepsis,
which makes it suitable for studying mechanisms of che-
merin action in sepsis host response.
In future studies, it will be important to examine dif-
ferent chemerin isoforms and their distribution to these
effects as well as the underlying mechanisms. Prospect-
ive clinical trials are needed to confirm the prognostic
value of chemerin in sepsis.
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Key messages
 Circulating chemerin levels are increased in
peritoneal sepsis compared with control and T2D,
while adipose tissue mRNA expression is decreased.
 The murine PCI model of peritoneal sepsis reliably
reflects changes of circulating chemerin and adipose
tissue mRNA expression in humans.
 Circulating chemerin levels are associated with
disturbed glucose homeostasis and insulin resistance
in sepsis.
 Circulating chemerin levels seem to be associated
with prognosis, depending on glycaemic status.
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